Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

How Has The Leber Congenital Amaurosis Market Size Shifted, And What Is the Outlook Through 2034?

The market size of leber congenital amaurosis has been gradually increasing over the past few years. It is predicted to expand from a size of $1.01 billion in 2024 to $1.06 billion in 2025, displaying a compound annual growth rate (CAGR) of 4.9%. The growth witnessed in the past can be credited to the heightened consciousness about rare ocular disorders, amplified government financial aid, advancements in diagnostic methods, growth of eye research establishments, and patient advocacy efforts.

Anticipations are high for robust expansion in the Leber congenital amaurosis market size over the ensuing years. The market is set to escalate to$1.31 billion by 2029, growing at a compound annual growth rate (CAGR) of 5.5%. The prospective growth can be credited to factors such as the surge in gene therapy investments, the rising occurrence of inherited retinal diseases, green lights from regulators for novel treatments, advanced clinical trials, and increased healthcare spending. Noteworthy trends during the forecast period comprise the emergence of CRISPR-based treatments, the heightened collaboration among biotechnology companies, the growth of personalized medicine, the broadening of teleophthalmology, and the advancement in retinal imaging technology.

Download a free sample to assess the report’s scope and structure:

https://www.thebusinessresearchcompany.com/sample.aspx?id=22033&type=smp

What Are the Primary Drivers Supporting the Market Growth of the Leber Congenital Amaurosis Market?

The surge in incidences of inherited retinal diseases is believed to boost the leber congenital amaurosis (LCA) market. These diseases are genetic conditions that affect the retina – the light-sensitive tissue at the rear of the eye which is crucial for vision. The rise in these diseases is due to the enhancement in genetic testing, increased awareness and diagnosis, as well as extended life expectancy. Due to the progress in genetic testing, diagnosing inherited retinal diseases has become easier, leading to the discovery of more such cases. Leber congenital amaurosis plays a key role in deepening the understanding of these diseases by unveiling the genetic mutations and disease mechanisms, which helps in creating focussed therapies and treatments. As an example, the UK Parliament’s House of Commons Library, a government establishment in the UK, reported in January 2025 that approximately 25,000 people in the UK had inherited retinal diseases in 2024, marking a yearly rise of 2%. Hence, the rising incidents of inherited retinal diseases are powering the growth in the leber congenital amaurosis market.

Which Primary Segments of the Leber Congenital Amaurosis Market Are Driving Growth and Industry Transformations?

The leber congenital amaurosismarket covered in this report is segmented –

1) By Treatment Type: Gene Therapy; Pharmaceutical Drugs; Retinal Prosthesis; Assistive Devices; Other Treatments

2) By Age Of Onset: Congenital Leber Congenital Amaurosis (LCA) (From Birth); Early Childhood Leber Congenital Amaurosis (LCA) (1-5 Years); Late-Onset Leber Congenital Amaurosis (LCA) (6 Years And Above)

3) By Distribution Channel:; Direct Tender; Retail Sales

4) By End User: Hospitals; Specialized Eye Clinics; Ophthalmology Research Centers; Home Care Settings; Other End Users

Subsegments:

1) By Gene Therapy: RPE65 Gene Replacement Therapy; CRISPR-Based Gene Editing; AAV (Adeno-Associated Virus) Vector Therapy; Emerging Experimental Gene Therapies

2) By Pharmaceutical Drugs: Retinoid-Based Therapies; Neuroprotective Agents; Anti-Inflammatory Drugs; Antioxidant Therapies

3) By Retinal Prosthesis: Implantable Retinal Chips; Artificial Retinal Stimulation Devices; Bionic Eye Technology

4) By Assistive Devices: Low Vision Aids; Screen Readers and Braille Devices; Mobility Aids for Vision Impairment

5) By Other Treatments: Stem Cell Therapy; Optogenetics-Based Treatments; Visual Rehabilitation Programs; Nutritional and Dietary Interventions

Request customized data on this market:

https://www.thebusinessresearchcompany.com/customise?id=22033&type=smp

Which Regions Are Key Players in the Growth of the #What Are the Primary Drivers Supporting the Market Growth of the Leber Congenital Amaurosis Market?# Market?

North America was the largest region in the leber congenital amaurosis market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the leber congenital amaurosis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

What Are the Most Significant Market Trends in the Leber Congenital Amaurosis Market?

Key leber congenital amaurosis market players are channeling their efforts towards creating groundbreaking solutions like RNA-based treatments. This approach improves vision restoration and management of the disease through the use of RNA molecules targeted at genetic processes. mRNA vaccines, siRNA therapies, antisense oligonucleotides, and RNA aptamers are among these treatments. For example, Laboratoires Théa S.A.S., a pharmaceutical firm based in France, unveiled Sepul Bio in January 2025. This specialized business division endeavors to propel RNA therapies forward for inherited retinal diseases, specifically focusing on sepofarsen for leber congenital amaurosis 10 (LCA10) and ultevursen for USH2A-linked retinitis pigmentosa. Following the successful administration of the first dosage to a patient in the LUNA Phase 2b clinical trial for ultevursen, Sepul Bio is set to make considerable progress in tackling these uncommon genetic disorders.

View the full report here:

https://www.thebusinessresearchcompany.com/report/leber-congenital-amaurosis-global-market-report

What Parameters Are Used to Define the Leber Congenital Amaurosis Market?

Leber congenital amaurosis (LCA) is a genetic eye disorder that causes severe vision loss or blindness from infancy due to mutations affecting the retina’s ability to detect light. It is characterized by poor visual response, involuntary eye movements (nystagmus), and extreme farsightedness resulting from disrupted photoreceptor function and progressive retinal degeneration.

Purchase the full report and get a swift delivery:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=22033

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Europe +44 7882 955267

Asia & Others +44 7882 955267 & +91 8897263534

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model